EP283/#999 Metabolomics showed that lipid metabolism contributed tumor growth of EOC via LSR

Objectives

Previously, we identified lipolysis-stimulated lipoprotein receptor (LSR) as a new target of epithelial ovarian cancer (EOC), and we reported anti-tumor effect of our newly developed monoclonal antibody (mAb) against LSR-positive EOC cells in vitro and in vivo. We also demonstrated that LSR promoted uptake of lipid metabolite in EOC cells, however, that pathway is still unclear. In this study, we performed metabolomic analysis and investigated the metabolic pathway of EOC via LSR using high-fat diet (HFD) mouse.

Methods

We established HFD mouse model and evaluated the tumor growth of LSR-positive EOC cell line and anti-tumor effect of anti-LSR mAb in this model. Moreover, we obtained serum samples from normal-diet (ND) and HFD mouse, and performed metabolomic analysis. Finally, we analyzed lipid metabolites profile of HFD mouse compared to ND mouse.

Results

Tumor growth of LSR-positive EOC cells was significantly promoted in HFD mouse (p < 0.05) and anti-LSR mAb showed stronger anti-tumor effect in HFD mouse than that in ND mouse (57.2% and 26,6%, respectively). Metabolomic analysis using HFD and ND mouse serum detected 210 metabolites and The Human Metabolome Database provided comprehensive information of 83 metabolites. Principal component analysis and cluster analysis using these metabolites showed obviously different metabolic properties between ND and HFD mouse. Partial Least Squares-Discriminant Analysis showed significantly high score of lipid metabolites in HFD mouse including a-Tocopherol and cholesterol.

Conclusions

Metabolomics showed the activation of lipid metabolism in HFD mouse and suggested that LSR contributed tumor growth via lipid metabolism.